超碰在线视频为您找到"

atreca

"相关结果

Novel Therapies for Cancer and Emerging Targets - …www.pegsummiteurope.com/cancer-therapyThe field of biologic drug development for cancer therapies has been greatly energized by the broad spectrum of innovative approaches and their stunning success.

The field of biologic drug development for cancer therapies has been greatly energized by the broad spectrum of innovative approaches and their stunning success.
www.pegsummiteurope.com/cancer-therapy

Programmed Cell Death 1 (PD-1) Ligand (PD-L1) …ascopubs.org/doi/full/10.1200/PO.16.00030PurposeDrugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway show significant clinical activity across several tumor types.

PurposeDrugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway show significant clinical activity across several tumor types.
ascopubs.org/doi/full/10.1200/PO.16.00030

Atrecahttps://www.atreca.com/aboutGuy Cavet, PhD Chief Technical Officer. Dr. Cavet is a founder of Atreca. He previously led informatics and computational biology at multiple biotechnology and information technology companies, including as a Vice President at Crescendo Bioscience, where he was instrumental in developing Vectra® DA, their marketed diagnostic product.

Guy Cavet, PhD Chief Technical Officer. Dr. Cavet is a founder of Atreca. He previously led informatics and computational biology at multiple biotechnology and information technology companies, including as a Vice President at Crescendo Bioscience, where he was instrumental in developing Vectra® DA, their marketed diagnostic product.
www.atreca.com/about

About Us | BioClin Therapeuticsbioclintherapeutics.com/about.htmlOverview. BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need.

Overview. BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need.
bioclintherapeutics.com/about.html

Portfolio — APTUShttps://aptustherapeutics.com/portfolioPortfolio. APTUS Therapeutics invests in some of the most promising opportunities in the US and in Asia. Please contact us for more information.

Portfolio. APTUS Therapeutics invests in some of the most promising opportunities in the US and in Asia. Please contact us for more information.
aptustherapeutics.com/portfolio

Preclinical and Translational Immuno-Oncologywww.triconference.com/Preclinical-Translational-Immuno-OncologyThe 25th International Molecular Medicine Tri-Conference is the industry’s Preeminent Event on Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics and Information Technology.

The 25th International Molecular Medicine Tri-Conference is the industry’s Preeminent Event on Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics and Information Technology.
www.triconference.com/Preclinical-Translational-Im...

Atrecahttps://www.atreca.comMedia/News. Atreca Announces Publication of HIV Research in Cell May 03, 2018; Atreca Announces John A. Orwin Appointed President and CEO Atreca Co-Founder Dr. Tito A. Serafini Will Serve as Chief Strategy Officer Lead Anti-Cancer Candidate Slated to Enter Clinical Testing in 2019 April 19, 2018

Media/News. Atreca Announces Publication of HIV Research in Cell May 03, 2018; Atreca Announces John A. Orwin Appointed President and CEO Atreca Co-Founder Dr. Tito A. Serafini Will Serve as Chief Strategy Officer Lead Anti-Cancer Candidate Slated to Enter Clinical Testing in 2019 April 19, 2018
www.atreca.com

Board of Directors - Retrophin, Inc.www.retrophin.com/content/company/board-of-directors.phpGARY A. LYONS Chairman . Mr. Lyons has been a member of the Board of Directors of Retrophin, Inc. since 2014 and assumed the role of Chairman in May of 2016.

GARY A. LYONS Chairman . Mr. Lyons has been a member of the Board of Directors of Retrophin, Inc. since 2014 and assumed the role of Chairman in May of 2016.
www.retrophin.com/content/company/board-of-directo...

Precision: Breast Cancer conference in Boston 2018 - …precisionbreastcancer.comAn exclusive, annual biopharma conference providing insights into the research and development of cutting edge treatments for Breast Cancer and a networking forum for precision medicine leaders in this space.

An exclusive, annual biopharma conference providing insights into the research and development of cutting edge treatments for Breast Cancer and a networking forum for precision medicine leaders in this space.
precisionbreastcancer.com